Caitong International Asset Management’s SAB Biotherapeutics SABS Stock Holding History

Caitong International Asset Management’s Portfolio SABS Stock Details SABS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$617	Buy	+161	New	+$642	﹤0.01%	1577

Other funds holding SABS

Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return

Caligan Partners New York $1.5B AUM 518.95% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Caitong International Asset Management's SABS Position: Q1 2026 in Review

Caitong International Asset Management opened a new position in SAB Biotherapeutics (SABS) in Q1 2026: 161 shares worth $617. The stake represents ﹤0.01% of the portfolio and ranks #1577 among its holdings.

76 funds tracked by Wall St. Rank hold SABS as of Q1 2026.

Caitong International Asset Management held 161 shares of SAB Biotherapeutics worth $617 as of Q1 2026.
SAB Biotherapeutics was a new Caitong International Asset Management position in Q1 2026.
SAB Biotherapeutics made up ﹤0.01% of Caitong International Asset Management's portfolio in Q1 2026, its #1577 holding.
76 funds tracked by Wall St. Rank held SAB Biotherapeutics as of Q1 2026.

Based on Caitong International Asset Management's 13F filing for Q1 2026, filed 11 May 2026.